Pharmaceuticals
Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO
～Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS inJapan and Asia～ TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, today ...
2024-04-01 14:30
2123
LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)
* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC * FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to fulfill the unmet medical needs of people affecte...
2024-03-29 21:00
3571
73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis
SAN FRANCISCO, March 29, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their cor...
2024-03-29 20:40
2963
Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SHANGHAI, March 29, 2024 /PRNewswire/ -- Alebund Pharmaceuticals
2024-03-29 20:00
2399
IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma
SHANGHAI and NANJING, China and SAN JOSE, Calif., March 29, 2024 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced thatChina National Medical Products Administratio...
2024-03-29 17:20
2148
Jacobio Pharma Announces 2023 Annual Results
BEIJING, SHANGHAI and BOSTON, March 28, 2024 Jacobio/PRNewswire/ -- Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue wasRMB63.5 million, the R&D investment wasRMB372 million, the cash and cash equivalent at...
2024-03-29 08:50
5299
Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade
SEONGNAM, South Korea and ATLANTA, March 28, 2024 /PRNewswire/ --
Bridge Biotherapeutics (KQ288330)
2024-03-29 06:00
4920
Harbour BioMed Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncol...
2024-03-28 22:10
4505
Tigermed Reports Full Year 2023 Results
HANGZHOU, China, March 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...
2024-03-28 18:31
4613
Ascentage Pharma Announces 2023 Annual Results
SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During...
2024-03-27 22:30
3200
CARsgen Announced 2023 Annual Results
SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights * Z...
2024-03-27 20:50
3148
Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development
SHANGHAI, March 27, 2024 /PRNewswire/ -- Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights: The new era sees the transition towards digitalization and intelligence. Following this trend, we have been thinking and planning the transformative path of digitali...
2024-03-27 20:00
2214
YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean
SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean. The event will take place fromApril 9th to 11th, 2024, at the esteemed...
2024-03-27 20:00
1989
Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology
SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge
Biotherapeutics (KQ288330)
2024-03-27 06:00
1470
WuXi Biologics Reports Solid 2023 Annual Results
Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross Profit Rose by 1.5% to RMB6,827.9 Million Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew by 101.7% Y-o-Y "R" in CRDMO Thrived with Extended Part...
2024-03-26 21:53
3446
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
NANJING, China, March 26, 2024 /PRNewswire/ -- PharmaBlock (Stock code: 300725.SZSE), a global, fully integrated CRDMOwith a focus on innovative chemistry and low-carbon manufacturing, is proud to announce that it has been awarded the 2024 CMO Excellence in Green Chemistry Award by the American ...
2024-03-26 20:00
1905
TiumBio Submits CTA for Phase 1b Clinical Trial of TU7710, a Long-acting Recombinant Activated Factor VII, in Hemophilia A or B Patients
* TU7710 has the potential to be a highly effective and long-acting treatment for bleeding episodes as well as for preventing bleeding during surgery or invasive procedures in hemophilia patients with inhibitors * Interim results from an ongoing Phase 1a study in healthy male volunteers will ...
2024-03-26 20:00
1576
100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer
SAN FRANCISCO, March 21, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their ...
2024-03-21 20:30
2206
FDA Grants Orphan Drug Designation to Cevidoplenib for ITP
PANGYO, South Korea, March 21, 2024 /PRNewswire/ -- Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP). Oscotec has successfully completed phase 2 study in patients wit...
2024-03-21 20:00
2140
Biosion to Present Three Posters at the 2024 AACR Meeting
NEWARK, Del. and NANJING, China, March 21, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets, including BSI-111, an anti-CD16a monoclonal antibody, BSI-730, a HER2/PD-L1 bispec...
2024-03-21 19:00
2593
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 325 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 301 media titles]
2026-02-24 16:13
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 288 media titles]
2026-02-23 10:09